Almac Sciences of Seagoe have gained another two main awards on the Northern Ireland business scene – for Excellence in Innovation and in Technology.
The Portadown company has been consistent winners over the 12 years of the awards, which are sponsored by the Belfast Telegraph in association with British Airways.
The winning Excellence in Innovation entry focussed on the development of Almac’s Antibody Drug Conjugation (ADC) offering provided by the Science’s biocatalysis group headed up by Professor Tom Moody. They have developed the ADC science from the laboratory into the successful business market.
The trophy was presented by Kevin Traynor, Belfast Telegraph’s Digital Director, to Dr William Watters, Isotope Chemistry Manager at Almac’s Sciences Business Unit. The other two finalists in this category were Core Systems and Randox Laboratories.
The Excellence in Technology award recognised the advances made by the diagnostics team in relation to recently announced DNA Damage Repair Deficiency (DDRD) research. This new technology offers significant advances in the treatment of cancer and has recently been the subject of a collaboration with US-based Genomic Health to bring its benefits to patients worldwide.
The trophy was collected by Michael Sloan, Vice President Business Development for the Diagnostics Business Unit, from Karen Blair, Managing Director, Cleaver Fulton Rankin, which sponsored the award. Other finalists in this category were PathXL and Taggled Ltd.
Alan Armstrong, CEO, Almac Group said, “We are delighted to receive these important awards. They are a tremendous tribute to the pioneering work carried out on a daily basis by our dedicated and talented teams.
“It is especially pleasing to achieve recognition for our work against such strong local competition and is testimony to our innovation within the pharmaceutical and biotech industry.”